Search
for
Sort by
Research 31–60 of 1000+
- Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Effectiveness of Baricitinib on Nail Alopecia Areata: A 48-Week Single-Center Retrospective Study
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Psychophysiological Mechanisms of Stress Impact on Hair Loss Processes
- Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- New drugs under investigation for the treatment of alopecias
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Survey of pediatric dermatologist views on treatment for alopecia areata
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Single‐cell transcriptomics reveals a senescence‐associated IL ‐6/ CCR6 axis driving radiodermatitis
- Emerging role of baricitinib in dermatology practice: All we need to know!
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Janus Kinase (JAK) Inhibitors in Dermatology: An Update and Critical Review
- Markers of inflammation, metabolic disorders, and principles of treatment for alopecia areata in children
- Janus Kinase inhibitors in dermatology: a review
- Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
- Medical Therapies
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- BH14 Irish dermatologists’ experience with Janus kinase inhibitors in alopecia areata
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)